CLINICAL TRIALS
Clinical trials team
LIRIC (UVASMET) has the infrastructure, staffing, and institutional support required to conduct clinical trials with high scientific, operational, and ethical standards. The center is supported by a multidisciplinary clinical team that includes experienced physicians who oversee medical supervision, participant evaluation, and safety monitoring. Study coordinators and data managers ensure accurate data collection, secure storage, and regulatory compliance, safeguarding the quality and traceability of research outcomes. Clinical activities are further supported by up to nurses who assist with patient care, protocol procedures, and ongoing follow-up, alongside qualified dietitians who contributes nutritional assessment and counseling, particularly relevant for dietary or metabolic studies.
Additionally, LIRIC has laboratory technicians who manage sample processing and coordinate laboratory procedures. The center is equipped with modern laboratory devices capable of handling blood and other biological samples safely and efficiently, ensuring proper preparation, storage, and analysis. Coordination with the pharmacy service enables secure storage, dispensing, and monitoring of investigational products in line with regulatory and safety requirements.
Administrative framework
LIRIC’s work is integrated within a solid administrative framework supported by the Research Institute IRB CatSud and the Hospital Universari Salut Sant Joan de Reus. These institutions provide operational oversight, logistical support, and regulatory management. Hospital facilities dedicated to conducting clinical assays ensure appropriate space, equipment, and conditions for patient visits, clinical procedures, and sample collection.
Importantly, all research activities are reviewed and supervised by the Ethical Committee, guaranteeing strict adherence to ethical standards, participant protection, and compliance with Good Clinical Practice (GCP) guidelines.
Together, this comprehensive infrastructure allows LIRIC (UVASMET) to conduct clinical trials with reliability, professionalism, and full regulatory and ethical compliance.
CONTACT FOR ADMINISTRATIVE INFORMATION :
Active Clinical Trials
A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event – MOVE-Lp(a) J2O-MC-EKBG
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients with Heterozygous Familial Hypercholesterolaemia.
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia (MK-0616-019)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Cardiovascular Disease or Are at Risk for a First Cardiovascular Event (J3L-MC-EZEF)
An Open-Label Extension Study of Olezarsen (ISIS 678354) .Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) (ISIS 678354-CS15)
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
